The Role of Beetroot Extract in Overcoming Chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide Regimen by Targeting Immune Response in Tumor Microenvironment: A Preclinical Study in Mammary Adenocarcinoma Rats

Asian Pac J Cancer Prev. 2022 Mar 1;23(3):1061-1068. doi: 10.31557/APJCP.2022.23.3.1061.

Abstract

Objective: This study aims to determine the role of beetroot extract in overcoming the chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide (NAC) regimens with a target immune response in the tumour microenvironment at the pre-clinical stage.

Methods: This study was conducted on rats with 7,12-Dimethyl Benz (α) Anthracene (DMBA) induced mammary adenocarcinoma. Adriamycin Cyclophosphamide was given in 4 cycles, whereas beetroot extract was administered three times each cycle. Observations of CD8 T cells and Myeloid Derivative Suppressive Cells (MDSC) expression levels and pathological responses were carried out on tumour tissue taken at the end of the observation.

Results: Supplementation of beetroot extract to NAC could significantly increase CD8 T cells and decrease MDSC in the tumour microenvironment. The addition of beetroot extract gave a better pathological response.

Conclusion: Beetroot extract enhances the immune response in the tumor microenvironment so that it has the potential to overcome chemoresistance in NAC.<br />.

Keywords: Beetroot; CD8 T cells; Chemoresistance; Myeloid Derivative Suppressive Cells; Neoadjuvant Adriamycin-Cyclophosphamide.

MeSH terms

  • Adenocarcinoma*
  • Animals
  • Breast Neoplasms* / pathology
  • Cyclophosphamide / pharmacology
  • Doxorubicin / pharmacology
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Immunity
  • Neoadjuvant Therapy
  • Plant Extracts / pharmacology
  • Rats
  • Tumor Microenvironment

Substances

  • Plant Extracts
  • Doxorubicin
  • Cyclophosphamide